261 related articles for article (PubMed ID: 19384573)
1. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
[TBL] [Abstract][Full Text] [Related]
2. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model.
Yadav SK; Prakash J; Chouhan S; Westfall S; Verma M; Singh TD; Singh SP
Neurochem Int; 2014 Jan; 65():1-13. PubMed ID: 24333323
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of extract of Bacopa monnieri and Mucuna pruriens as neuroprotectant in MPTP model of Parkinson’s disease.
Singh B; Pandey S; Verma R; Ansari JA; Mahdi AA
Indian J Exp Biol; 2016 Nov; 54(11):758-66. PubMed ID: 30179419
[TBL] [Abstract][Full Text] [Related]
6. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Lieu CA; Kunselman AR; Manyam BV; Venkiteswaran K; Subramanian T
Parkinsonism Relat Disord; 2010 Aug; 16(7):458-65. PubMed ID: 20570206
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-Reduced
Johnson SL; Park HY; DaSilva NA; Vattem DA; Ma H; Seeram NP
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30131460
[No Abstract] [Full Text] [Related]
9.
Rai SN; Birla H; Singh SS; Zahra W; Patil RR; Jadhav JP; Gedda MR; Singh SP
Front Aging Neurosci; 2017; 9():421. PubMed ID: 29311905
[TBL] [Abstract][Full Text] [Related]
10.
Kamkaen N; Chittasupho C; Vorarat S; Tadtong S; Phrompittayarat W; Okonogi S; Kwankhao P
Molecules; 2022 May; 27(10):. PubMed ID: 35630617
[TBL] [Abstract][Full Text] [Related]
11. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G
J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Pinna A; Pontis S; Borsini F; Morelli M
Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
[TBL] [Abstract][Full Text] [Related]
13. Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
Kim KS; Zhao TT; Shin KS; Park HJ; Cho YJ; Lee KE; Kim SH; Lee MK
J Med Food; 2017 Jan; 20(1):11-18. PubMed ID: 28005447
[TBL] [Abstract][Full Text] [Related]
14. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
15. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
Katzenschlager R; Evans A; Manson A; Patsalos PN; Ratnaraj N; Watt H; Timmermann L; Van der Giessen R; Lees AJ
J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1672-7. PubMed ID: 15548480
[TBL] [Abstract][Full Text] [Related]
16. Seed extract of Thai Mucuna pruriens (L.) DC. var. pruriens enhances sexual performance and improves male reproductive damages in ethanol-induced rats.
Tangsrisakda N; Kamollerd T; Taoto C; Bunsueb S; Chaimontri C; Choowong-In P; Lapyuneyong N; Wu AT; Thukhammee W; Wattanathorn J; Arun S; Sawatpanich T; Iamsaard S
J Ethnopharmacol; 2022 Jun; 292():115219. PubMed ID: 35339625
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Manyam BV; Dhanasekaran M; Hare TA
Phytother Res; 2004 Sep; 18(9):706-12. PubMed ID: 15478206
[TBL] [Abstract][Full Text] [Related]
18. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
19. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
[TBL] [Abstract][Full Text] [Related]
20. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]